TEM Stock Jumps As Tempus AI Lands Big Pharma Data Deals
Tempus AI Inc. (TEM) stock rose 10.52% on news of multi-year data deals with Bristol Myers Squibb, Pathos, Moderna, and Merck. TEM's stock has been volatile, trading between $64.03 and $80.70 recently. The company reported $1.27B revenue, 73.5% gross margin, but negative operating margins and free cash flow. TEM is priced at 9x sales with a rich price-to-book ratio, and has a solid balance sheet with a current ratio of 3.3.
How this was made
The 30-second read
Why it matters
The core trading driver is incremental visibility from large, multi-year pharma partnerships (especially BMS through 2031) plus expansion into neurology and additional oncology-related collaboration, offset by ongoing losses and free-cash-flow burn.
Market read
Traders are likely to treat the headline as a near-term catalyst for TEM’s momentum, with follow-through dependent on how quickly contracted deals convert into measurable financial performance.
What to watch
The article does not provide deal economics beyond headline terms (e.g., revenue recognition timing, margin impact, or operational milestones), which could drive post-news re-rating once details emerge.
Background
The piece frames TEM as an AI-driven healthcare data and platform company and links its recent price action to newly highlighted pharma data licensing and collaboration agreements.
Ticker impact
Tempus AI (TEM) is reported to have signed a multi-year Bristol Myers Squibb data licensing deal running through 2031, plus additional pharma collaborations.
Likely upward bias as traders price in visibility from large, multi-year pharma data deals, with volatility around execution and cost concerns.
The article attributes TEM’s jump to specific, named multi-year agreements (BMS through 2031, Pathos $55M, and Moderna-Merck expansion) that directly increase contracted revenue visibility, while also noting negative operating margins and free cash flow.
Market effects
Reinforces demand for AI-enabled healthcare data platforms and could lift sentiment for precision-medicine data infrastructure providers.
Primarily US-listed healthcare/biotech sentiment, with limited direct regional spillover implied.
Supports a broader global narrative of pharma adopting multimodal AI and longitudinal datasets for drug discovery and clinical development.
Counterpoint
The deals may not immediately translate into profitability, and the stock’s momentum could fade if investors focus on cash burn, leverage, or slower-than-expected commercialization.
Key entities
- companyTempus AI Inc.
NASDAQ-listed AI healthcare data and platform provider whose stock is described as jumping on pharma data deal news.
- companyBristol Myers Squibb
Pharma partner signing a multi-year Tempus AI multimodal oncology data and Lens AI licensing agreement through 2031, and involved in a three-party collaboration.
- companyPathos
Counterparty in a five-year $55M neurology dataset deal described as using Tempus Foundry AI for Alzheimer’s and other neurological drug development.
- companyModerna
Named in an expanded multi-year collaboration with Tempus and Merck around intismeran autogene and KEYTRUDA-related individualized neoantigen therapy.
- companyMerck
Named in the expanded multi-year collaboration with Tempus and Moderna around intismeran autogene paired with KEYTRUDA.
